Center of Cognitive and Behavioral Disorders.
Department of Neurosciences and Behaviour, University of Pavia.
Alzheimer Dis Assoc Disord. 2019 Jul-Sep;33(3):282-284. doi: 10.1097/WAD.0000000000000289.
The use of biomarkers has recently supported the association between Alzheimer disease (AD) pathology and the logopenic variant of primary progressive aphasia (PPA). We aim to investigate possible differences in cerebrospinal fluid (CSF) biomarker concentrations in the three PPA variants, and to assess any agreement between CSF biomarkers and (18)F-florbetapir PET. A group of 10 PPA were retrospectively enrolled. Patients with logopenic variant (lvPPA) showed different levels of Aβ1-42 and p-tau compared to nonfluent/agrammatic and semantic variants (nfv/svPPA). All nfv/svPPA patients had negative amyloid PET. Among the lvPPA group, a negative amyloid PET was found only in one patient, who was also the only one to display a normal CSF. Thus, this small cohort appeared to display an excellent agreement between CSF and (18)F-florbetapir PET and suggest that these examinations may have the same validity in detecting in vivo evidence of AD pathology in PPA clinical variants.
生物标志物的应用最近支持了阿尔茨海默病（AD）病理学与原发性进行性失语症（PPA）中的失语法变异之间的关联。我们旨在研究三种 PPA 变异中脑脊液（CSF）生物标志物浓度的可能差异，并评估 CSF 生物标志物与（18）F-氟比他哌 PET 之间的任何一致性。一组 10 名 PPA 患者被回顾性纳入研究。与非流利/语法障碍和语义变异型（nfv/svPPA）相比，失语法变异型（lvPPA）患者的 Aβ1-42 和 p-tau 水平不同。所有 nfv/svPPA 患者的淀粉样蛋白 PET 均为阴性。在 lvPPA 组中，只有一名患者的淀粉样蛋白 PET 为阴性，也是唯一一名 CSF 正常的患者。因此，这个小队列似乎在 CSF 和（18）F-氟比他哌 PET 之间显示出极好的一致性，并表明这些检查在检测 PPA 临床变异中 AD 病理学的体内证据方面可能具有相同的有效性。
